Blood glucose variability
Conditions
Interventions
Two groups:Needleless syringe versus special flling pen
Sponsors
Department of Endocrinology, Tangdu Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. For men or women aged 18-70 years, women of childbearing age should take adequate contraceptive measures to minimize the risk of pregnancy; 2. Patients who meet the diagnostic criteria of type 2 diabetes and have a course of more than half a year; 3. BMI 18 Kg/m2 to 30Kg/m2; 4. Patients who received once daily injection of insulin glargine and one or three oral drugs (excluding secretagogue agents) had a daily total dose of insulin glargine 12 IU to 50 IU, and used insulin glargine for more than 1 month; 5. Patients with fasting venous blood glucose between 5.0 and 9.0 mmol/L; 6. Patients who have read and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who have conflict of interest with this study; 2. Patients with poor glycemic control and unable to participate in this study, such as repeated hypoglycemia, diabetic ketoacidosis or hyperosmolar coma history, and other adverse events of blood glucose control; 3. Patients with severe diabetic complications, such as diabetic foot, diabetic nephropathy, etc; 4. Patients with severe cardiovascular events in recent 6 months; 5. Patients with deficiency or low immunity due to hormone or immunosuppressive therapy; 6. Patients with NSAIDs; 7. Patients with sulfonylureas and insulin secretagogues; 8. Patients with a history of tumor; 9. Patients with a history of unstable or rapidly progressive kidney disease; 10. Patients with unstable major mental history; 11. Patients with a history of hemoglobinopathy (such as sickle cell anemia, thalassemia, sideroblastic anemia); 12. Pregnant or lactating women; 13. Patients with definite infection recently, such as urinary tract infection and pneumonia; 14. Patients with recent active bleeding of important organs, such as gastric hemorrhage, cerebral hemorrhage, etc; 15. Patients with exfoliative dermatitis, impetigo, pyogenic infection and other skin diseases; 16. Patients with a history of acute pancreatitis or pancreatectomy; 17. Any situation that the researcher considers may cause the subject unable to complete the study or may cause significant risk to the subject. 18. Patients with the following laboratory results: (1) Obvious abnormal liver function or active liver disease (AST > 3.0 times of upper normal limit or ALT > 3.0 times of normal upper limit); (2) Creatinine clearance rate was less than 60 ml / min; (3) Anemia caused by any cause; (4) The pregnancy test results of women of childbearing age were positive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood glucose variability; | — |
Secondary
| Measure | Time frame |
|---|---|
| Insulin consumption and health economics assessment; | — |
Countries
China
Contacts
Public ContactGao Bin
Department of Endocrinology, Tangdu Hospital
Outcome results
None listed